Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Antiandrogens  COVID-19 treatment studies for Antiandrogens  C19 studies: Antiandrogens  Antiandrogens   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 91% Improvement Relative Risk Ventilation 91% Recovery time 44% Recovery 33% Gomaa et al. NCT04487964 Glycyrrhizin RCT LATE TREATMENT Is late treatment with antiandrogens+boswellic acid beneficial for COVID-19? Double-blind RCT 50 patients in Egypt (June - November 2021) Faster recovery with antiandrogens+boswellic acid (p=0.001) Gomaa et al., Inflammopharmacology, doi:10.1007/s10787-022-00939-7 Favors glycyrrhizin Favors control
Advancing combination treatment with glycyrrhizin and boswellic acids for hospitalized patients with moderate COVID-19 infection: a randomized clinical trial
Gomaa et al., Inflammopharmacology, doi:10.1007/s10787-022-00939-7, NCT04487964 (history)
Gomaa et al., Advancing combination treatment with glycyrrhizin and boswellic acids for hospitalized patients with moderate.., Inflammopharmacology, doi:10.1007/s10787-022-00939-7, NCT04487964
Mar 2022   Source   PDF  
  All Studies   Meta
RCT with 50 hospitalized COVID+ patients in Egypt, 25 treated with glycyrrhizin and boswellic acid, showing improved recovery with treatment. Glycyrrhizin 60mg and boswellic acid 200mg bid for 2 weeks. NCT04487964 (history).
risk of death, 90.9% lower, RR 0.09, p = 0.05, treatment 0 of 25 (0.0%), control 5 of 25 (20.0%), NNT 5.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 14.
risk of mechanical ventilation, 90.9% lower, RR 0.09, p = 0.05, treatment 0 of 25 (0.0%), control 5 of 25 (20.0%), NNT 5.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 14.
recovery time, 44.0% lower, relative time 0.56, p < 0.001, treatment 25, control 25.
risk of no recovery, 33.3% lower, RR 0.67, p < 0.001, treatment 25, control 25, relative clinical status, day 14.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gomaa et al., 1 Mar 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Egypt, peer-reviewed, median age 60.0, 5 authors, study period June 2021 - November 2021, average treatment delay 6.0 days, this trial uses multiple treatments in the treatment arm (combined with boswellic acid) - results of individual treatments may vary, trial NCT04487964 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAntiandrogensAll
Abstract: Inflammopharmacology (2022) 30:477–486 Inflammopharmacology ORIGINAL ARTICLE Advancing combination treatment with glycyrrhizin and boswellic acids for hospitalized patients with moderate COVID‑19 infection: a randomized clinical trial Adel A. Gomaa1 · Hamdy S. Mohamed4 · Rasha B. Abd‑ellatief1 · Mohamed A. Gomaa2 · Doaa S. Hammam3 Received: 4 February 2022 / Accepted: 8 February 2022 / Published online: 1 March 2022 © The Author(s) 2022 Abstract Recent evidence points to a potential therapeutic role for glycyrrhizin(GR) and boswellic acids (BA) in the treatment of COVID-19 but conclusive evidence is lacking. Our aim is to investigate the efficacy of GR + BA versus placebo for the treatment of hospitalized patients with moderate SARS-CoV-2 or COVID-19 variants infection. The current study is a randomized, double-blind, placebo-controlled, single-center trial. Patients with SARS-CoV-2 or COVID-19 variants diagnosed by PCR test who were admitted to Sohag University hospital were eligible if they were at least 18 years of age and had moderate symptoms. Patients were randomly assigned to receive oral GR capsule (60 mg) and BA (200 mg) twice daily for 14 days or a matching placebo. All patients also received treatment with the institutional protocol for COVID-19. The primary outcome was mortality and time to recovery. Secondary outcome was clinical status score, 14 days after receiving study drugs. Adverse events from use of study drugs have been evaluated for up to 14 days. The trial is registered at (Identifier NCT04487964). During the 6-month enrollment period (June-November, 2021) only 50 patients (54% women; median age 60 years, IQR 54–65) met eligibility and were randomly assigned. Evaluation of the primary outcome at 14 days showed that there were five deaths in the placebo group and no deaths in the GR + BA group. With regard to recovery time, it was significantly shorter (p = 0.0001) in the group receiving GR + BA capsule compared to the placebo group (median 7.0; IQR 6.0–8.0 days vs. median 12.5; IQR 12–20 days). Clinical status on the ordinal score scale as a secondary outcome showed a significant difference between the GR + BA group (median (IQR) score, 2 [2–3]) and placebo groups (mean (IQR) score, 3 [3–5.5]). There was a significant decrease in CRB (p = 0.000041) in GR + BA compared with the placebo group. In conclusion, this safe, inexpensive, antiviral, immunomodulating and anti-inflammatory combination may be considered for use in mild to moderate infections of SARS-CoV-2 or COVID-19 variants. The study is limited by the small sample size; therefore, larger randomized trials are required. Keywords COVID-19 · Glycyrrhizin · Boswellic aids · Mortality rate · Time to recovery · Clinical status score Abbreviations BA Boswellic acids ACE2 Angiotensin-converting enzyme 2 * Adel A. Gomaa 1 Department of Medical Pharmacology, Faculty of Medicine, Assiut University, Assiut, Egypt 2 Department of Plastic Surgery, Faculty of Medicine, Assiut University, Assiut, Egypt 3 Department of Pharmacology & Toxicology, Faculty of Pharmacy, Assiut University, Assiut, Egypt 4 Department of Internal Medicine, Faculty of Medicine, Sohag University, Sohag, Egypt COVID-19 Coronavirus disease 2019 CRB C-reactive protein GR Glycyrrhizin HMGB1 High-mobility group box 1 protein HsGAPDH Human GAPDH IQR Interquartile rang NLRP3 Nod-like receptor..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop